Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas

BACKGROUND: Iniparib is a prodrug that converts to highly reactive cytotoxic metabolites intracellularly with activity in preclinical glioma models. We investigated the maximum tolerated dose (MTD) of iniparib with monthly (m) and continuous (c) temozolomide (TMZ) dosing schedules in patients with m...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Neurooncol
Autores principales: Blakeley, Jaishri O., Grossman, Stuart A., Mikkelsen, Tom, Rosenfeld, Myrna R., Peereboom, David, Nabors, L. Burt, Chi, Andrew S., Emmons, Gary, Ribas, Ignacio Garcia, Supko, Jeffrey G., Desideri, Serena, Ye, Xiaobu
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4869687/
https://ncbi.nlm.nih.gov/pubmed/26285766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-015-1876-0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares